<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681729</url>
  </required_header>
  <id_info>
    <org_study_id>EFC16720</org_study_id>
    <secondary_id>2020-003756-33</secondary_id>
    <secondary_id>U1111-1246-6913</secondary_id>
    <nct_id>NCT04681729</nct_id>
  </id_info>
  <brief_title>Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary&#xD;
      acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of&#xD;
      an H1-antihistamine&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU disease&#xD;
      control To demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU&#xD;
      local signs and symptoms (hives/wheals, itch, burning sensation and pain) after provocation&#xD;
      test To demonstrate the efficacy of dupilumab on primary acquired chronic inducible ColdU&#xD;
      disease activity To demonstrate improvement in health-related quality-of-life and overall&#xD;
      disease status and severity To evaluate the ability of dupilumab in reducing the proportion&#xD;
      of participants who require rescue therapy To evaluate the proportion of participants with&#xD;
      cold exposure triggered urticaria To evaluate safety outcome measures To evaluate&#xD;
      immunogenicity of dupilumab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of study for each participant will include 2-4 weeks of screening period, 24&#xD;
      weeks of treatment period and 12 weeks of post treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with negative ice cube provocation test at Week 24 compared with placebo</measure>
    <time_frame>Week 24</time_frame>
    <description>Negative ice cube provocation test is defined as the absence of a confluent hives/wheal at the entire skin site of exposure after ice cube provocation test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urticaria control test at Week 24 compared with placebo</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The UCT is a PRO questionnaire for assessing urticaria control. It is comprised of 4 items (UCT-4). The UCT-4 total score is 0-16, with a score of 16 for complete disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of well-controlled participants at Week 24 compared with placebo</measure>
    <time_frame>Week 24</time_frame>
    <description>The UCT is a PRO questionnaire for assessing urticaria control. It is comprised of 4 items (UCT-4). The UCT-4 total score is 0-16, with a score of 16 for complete disease control. Well-controlled is UCT-4 total score ≥12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an improvement of ≥3 in UCT-4 item from baseline to Week 24 compared with placebo</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The UCT is a PRO questionnaire for assessing urticaria control. It is comprised of 4 items (UCT-4). The UCT-4 total score is 0-16, with a score of 16 for complete disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in local wheal intensity at the provocation site at Week 12 and 24 using the wheal intensity Likert scale compared with placebo</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>The Wheal intensity Likert scale (ranging from 0 to 5) is a clinician-reported outcome measure comprised of a single item assessing the intensity of patients' cutaneous reaction rated as follows: 0=no wheals; 1=numerous small, noncoalescent wheals; 2= a large, regular, slightly edematous, coalescent wheal; 3=a large and moderately edematous wheal; 4=a large, regular, and significantly edematous wheal without pseudopodia; and 5=a large, very edematous wheal with pseudopodia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in local itch severity at the provocation site at Week 12 and 24 using the Peak Pruritus Numerical Rating Scale (NRS) compared with placebo</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>The peak pruritus NRS is a patient-reported outcome (PRO) comprised of a single item rated on a scale from 0 (&quot;No itch&quot;) to 10 (&quot;Worst itch imaginable&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in local skin burning sensation at the provocation site at Week 12 and Week 24 using the peak burning sensation NRS compared with placebo</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>The peak burning sensation NRS is a PRO comprised of a single item rated on a scale from 0 (&quot;No burning sensation&quot;) to 10 (&quot;Worst imaginable burning sensation&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in local pain severity at the provocation site at Week 12 and Week 24 using the peak pain sensation NRS compared with placebo</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>The peak pain NRS is a PRO comprised of a single item rated on a scale from 0 (&quot;No pain&quot;) to 10 (&quot;Worst imaginable pain&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with negative ice cube provocation test at Week 12 compared with placebo</measure>
    <time_frame>Week 12</time_frame>
    <description>Negative ice cube provocation test is defined as the absence of a confluent hives/wheal at the entire skin site of exposure after ice cube provocation test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Cold Urticaria Activity Score (ColdUAS) is a disease specific PRO questionnaire designed to determine cold urticaria disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of days with cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Cold Urticaria Activity Score (ColdUAS) is a disease specific PRO questionnaire designed to determine cold urticaria disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with severe cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Cold Urticaria Activity Score (ColdUAS) is a disease specific PRO questionnaire designed to determine cold urticaria disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of days with severe cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Cold Urticaria Activity Score (ColdUAS) is a disease specific PRO questionnaire designed to determine cold urticaria disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health-related quality-of-life (HRQoL) as measured by Dermatology Life Quality Index (DLQI) at Week 24 compared with placebo</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The DLQI is a PRO developed to measure dermatology-specific HRQoL in patients ≥16 years old. Overall scoring ranges from 0 to 30, with a high score indicative of a poor HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HRQoL as measured by Children's Dermatology Life Quality Index (CDLQI) at Week 24 compared with placebo</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The CDLQI is a validated questionnaire designed to measure the impact of skin disease on children's (≥12 to &lt;16 years old) HRQoL. The CDLQI total score is 0-30. The higher the score, the greater the impact is on the child's HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) of primary acquired chronic inducible ColdU at Week 12 and Week 24 compared with placebo</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>The PGIC is a 1-item questionnaire that asks the participant to provide the overall self-assessment of change in their chronic inducible ColdU on a 7-point scale, compared with just before participant started taking the study treatment. Response choices are: 0=&quot;Very much better&quot;, 1= &quot;Moderately better&quot;, 2=&quot;A little better&quot;, 3=&quot;No change&quot;, 4=&quot;A little worse&quot;, 5=&quot;Moderately worse&quot;, 6=&quot;Very much worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Global Impression of Severity (PGIS) of primary acquired chronic inducible ColdU at Week 12 and Week 24 compared with placebo</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>The PGIS is a 1-item questionnaire that asks participants to provide the overall self-assessment of their chronic inducible ColdU current severity on a 4 point scale. Response choices are: 1= &quot;None&quot;, 2=&quot;Mild&quot;, 3=&quot;Moderate&quot;, 4=&quot;Severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Cold Urticaria Quality of Life (ColdU QoL) at Week 24 compared with placebo</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>ColdU-QoL questionnaire is a disease-specific PRO questionnaire designed to assess the impact of cold urticaria on patients' health-related QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue therapy for primary acquired chronic induced ColdU during the planned treatment period compared with placebo</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants receiving rescue therapy for primary acquired chronic inducible ColdU during the planned treatment period compared with placebo</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with cold exposure urticaria requiring emergency medical care visit or treatment with epinephrine</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>At provocation test and/or at home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of participants experiencing treatment--emergent adverse events (TEAEs) or serious adverse events (SAEs)</measure>
    <time_frame>Throughout the study up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab over time</measure>
    <time_frame>Throughout the study up to Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Cold Urticaria</condition>
  <arm_group>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimens, on top of regular or as needed non-sedating H1-antihistamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,on top of regular/as needed non-sedating H1-antihistamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab SAR231893</intervention_name>
    <description>Pharmaceutical form:Injection solution Route of administration: Subcutaneous</description>
    <arm_group_label>Dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Injection solution Route of administration: Subcutaneous</description>
    <arm_group_label>Matched Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non sedating H1-antihistamine</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Dupilumab</arm_group_label>
    <arm_group_label>Matched Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Participant must be ≥12 years to 80 years of age inclusive at the time of signing the&#xD;
             informed consent&#xD;
&#xD;
          -  Participants who have a diagnosis of primary acquired chronic inducible ColdU defined&#xD;
             as recurrence of itchy wheals and/or angioedema due to cold for longer than 6 weeks&#xD;
             prior to screening visit (Visit 1)&#xD;
&#xD;
          -  Participants with positive ice cube provocation test, ie, presenting at least a&#xD;
             confluent hive/wheal on the exposed skin area, at the screening visit (Visit 1) and&#xD;
             randomization visit (Visit 2)&#xD;
&#xD;
          -  Participants meeting at least 1 of the following criteria despite regular/daily or as&#xD;
             needed use of H1-antihistamine (AH):&#xD;
&#xD;
               -  Urticaria Control Test (UCT) (4 item) &lt;12 at the screening visit (Visit 1) and&#xD;
                  randomization visit (Visit 2)&#xD;
&#xD;
               -  Within 6 months prior to the screening visit, documented medical history of cold&#xD;
                  exposure triggered anaphylaxis or oropharyngeal edema&#xD;
&#xD;
               -  Within 6 months prior to the screening visit, documented medical history of cold&#xD;
                  exposure triggered urticaria requiring emergency medical care visit or treatment&#xD;
                  with epinephrine&#xD;
&#xD;
          -  Participants using a study defined H1-antihistamine regularly/daily or as needed for&#xD;
             primary acquired chronic inducible cold urticaria Body weight ≥30 kg&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Clearly defined underlying etiology for urticaria other than primary acquired chronic&#xD;
             inducible ColdU&#xD;
&#xD;
          -  Presence of skin morbidities other than cold urticaria that may interfere with the&#xD;
             assessment of the study outcomes&#xD;
&#xD;
          -  Active atopic dermatitis&#xD;
&#xD;
          -  Severe concomitant illness(es) that, in the investigator's judgment, would adversely&#xD;
             affect the patient's participation in the study&#xD;
&#xD;
          -  Active tuberculosis or non-tuberculous mycobacterial infection, or a history of&#xD;
             incompletely treated tuberculosis unless documented adequately treated.&#xD;
&#xD;
          -  Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic&#xD;
             infection&#xD;
&#xD;
          -  Active chronic or acute infection requiring treatment with systemic antibiotics,&#xD;
             antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit&#xD;
             and during the screening period&#xD;
&#xD;
          -  Known or suspected immunodeficiency&#xD;
&#xD;
          -  Active malignancy or history of malignancy within 5 years before the baseline visit,&#xD;
             except completely treated in situ carcinoma of the cervix, completely treated and&#xD;
             resolved non-metastatic squamous or basal cell carcinoma of the skin&#xD;
&#xD;
          -  History of systemic hypersensitivity or anaphylaxis to omalizumab or any biologic&#xD;
             therapy, including any excipients&#xD;
&#xD;
          -  Participation in prior dupilumab clinical study, or have been treated with&#xD;
             commercially available dupilumab.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400003</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400005</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320001</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1023AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320005</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320002</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320004</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucumán</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320003</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240008</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5J 3S9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240007</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R 4H9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240009</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240001</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240005</name>
      <address>
        <city>Saint-Charles-Borromée</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240006</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1L 0H8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240002</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760002</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760004</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760006</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760005</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760001</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920003</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920005</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920008</name>
      <address>
        <city>Kamimashiki Gun</city>
        <state>Kumamoto</state>
        <zip>861-3101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920007</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920001</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920010</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>136-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists, Non-Sedating</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

